2,591 research outputs found
MalDA, Accelerating Malaria Drug Discovery
© 2021 The Authors The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions
MalDA, accelerating malaria drug discovery
The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions
Integration and mining of malaria molecular, functional and pharmacological data: how far are we from a chemogenomic knowledge space?
The organization and mining of malaria genomic and post-genomic data is
highly motivated by the necessity to predict and characterize new biological
targets and new drugs. Biological targets are sought in a biological space
designed from the genomic data from Plasmodium falciparum, but using also the
millions of genomic data from other species. Drug candidates are sought in a
chemical space containing the millions of small molecules stored in public and
private chemolibraries. Data management should therefore be as reliable and
versatile as possible. In this context, we examined five aspects of the
organization and mining of malaria genomic and post-genomic data: 1) the
comparison of protein sequences including compositionally atypical malaria
sequences, 2) the high throughput reconstruction of molecular phylogenies, 3)
the representation of biological processes particularly metabolic pathways, 4)
the versatile methods to integrate genomic data, biological representations and
functional profiling obtained from X-omic experiments after drug treatments and
5) the determination and prediction of protein structures and their molecular
docking with drug candidate structures. Progresses toward a grid-enabled
chemogenomic knowledge space are discussed.Comment: 43 pages, 4 figures, to appear in Malaria Journa
Transmembrane solute transport in the apicomplexan parasite Plasmodium
Apicomplexa are a large group of eukaryotic, single-celled parasites, with complex life cycles that occur within a wide range of different microenvironments. They include important human pathogens such as Plasmodium, the causal agent of malaria, and Toxoplasma, which causes toxoplasmosis most often in immunocompromised individuals. Despite environmental differences in their life cycles, these parasites retain the ability to obtain nutrients, remove waste products, and control ion balances. They achieve this flexibility by relying on proteins that can deliver and remove solutes. This reliance on transport proteins for essential functions makes these pathways excellent potential targets for drug development programmes. Transport proteins are frequently key mediators of drug resistance by their ability to remove drugs from their sites of action. The study of transport processes mediated by integral membrane proteins and, in particular, identification of their physiological functions and localisation, and differentiation from host orthologues has already established new validated drug targets. Our understanding of how apicomplexan parasites have adapted to changing environmental challenges has also increased through the study of their transporters. This brief introduction to membrane transporters of apicomplexans highlights recent discoveries focusing on Plasmodium and emphasises future directions
An evolutionary perspective on the kinome of malaria parasites
Malaria parasites belong to an ancient lineage that diverged very early from the main branch of eukaryotes. The approximately 90-member plasmodial kinome includes a majority of eukaryotic protein kinases that clearly cluster within the AGC, CMGC, TKL, CaMK and CK1 groups found in yeast, plants and mammals, testifying to the ancient ancestry of these families. However, several hundred millions years of independent evolution, and the specific pressures brought about by first a photosynthetic and then a parasitic lifestyle, led to the emergence of unique features in the plasmodial kinome. These include taxon-restricted kinase families, and unique peculiarities of individual enzymes even when they have homologues in other eukaryotes. Here, we merge essential aspects of all three malaria-related communications that were presented at the Evolution of Protein Phosphorylation meeting, and propose an integrated discussion of the specific features of the parasite's kinome and phosphoproteome
Lead optimization for new antimalarials and Successful lead identification for metalloproteinases: A Fragment-based approach Using Virtual Screening
Lead optimization for new antimalarials and Successful lead identification
for metalloproteinases: A Fragment-based approach Using Virtual Screening
Computer-aided drug design is an essential part of the modern medicinal
chemistry, and has led to the acceleration of many projects. The herein
described thesis presents examples for its application in the field of lead
optimization and lead identification for three metalloproteins.
DOXP-reductoisomerase (DXR) is a key enzyme of the mevalonate independent
isoprenoid biosynthesis. Structure-activity relationships for 43 DXR
inhibitors are established, derived from protein-based docking, ligand-based
3D QSAR and a combination of both approaches as realized by AFMoC. As part
of an effort to optimize the properties of the established inhibitor
Fosmidomycin, analogues have been synthesized and tested to gain further
insights into the primary determinants of structural affinity.
Unfortunately, these structures still leave the active Fosmidomycin
conformation and detailed reaction mechanism undetermined. This fact,
together with the small inhibitor data set provides a major challenge for
presently available docking programs and 3D QSAR tools. Using the recently
developed protein tailored scoring protocol AFMoC precise prediction of
binding affinities for related ligands as well as the capability to estimate
the affinities of structurally distinct inhibitors has been achieved.
Farnesyltransferase is a zinc-metallo enzyme that catalyzes the
posttranslational modification of numerous proteins involved in
intracellular signal transduction. The development of farnesyltransferase
inhibitors is directed towards the so-called non-thiol inhibitors because of
adverse drug effects connected to free thiols. A first step on the way to
non-thiol farnesyltransferase inhibitors was the development of an
CAAX-benzophenone peptidomimetic based on a pharmacophore model. On its
basis bisubstrate analogues were developed as one class of non-thiol
farnesyltransferase inhibitors. In further studies two aryl binding and two
distinct specificity sites were postulated. Flexible docking of model
compounds was applied to investigate the sub-pockets and design highly
active non-thiol farnesyltransferase inhibitor. In addition to affinity,
special attention was paid towards in vivo activity and species specificity.
The second part of this thesis describes a possible strategy for
computer-aided lead discovery. Assembling a complex ligand from simple
fragments has recently been introduced as an alternative to traditional HTS.
While frequently applied experimentally, only a few examples are known for
computational fragment-based approaches. Mostly, computational tools are
applied to compile the libraries and to finally assess the assembled
ligands. Using the metalloproteinase thermolysin (TLN) as a model target, a
computational fragment-based screening protocol has been established.
Starting with a data set of commercially available chemical compounds, a
fragment library has been compiled considering (1) fragment likeness and (2)
similarity to known drugs. The library is screened for target specificity,
resulting in 112 fragments to target the zinc binding area and 75 fragments
targeting the hydrophobic specificity pocket of the enzyme. After analyzing
the performance of multiple docking programs and scoring functions forand the most 14 candidates are selected for further analysis. Soaking
experiments were performed for reference fragment to derive a general
applicable crystallization protocol for TLN and subsequently for new
protein-fragment complex structures. 3-Methylsaspirin could be determined to
bind to TLN. Additional studies addressed a retrospective performance
analysis of the applied scoring functions and modification on the screening
hit. Curios about the differences of aspirin and 3-methylaspirin,
3-chloroaspirin has been synthesized and affinities could be determined to
be 2.42 mM; 1.73 mM und 522 μM respectively.
The results of the thesis show, that computer aided drug design approaches
could successfully support projects in lead optimization and lead
identification.
fragments in general, the fragments derived from the screening are docke
A brief overview of current drug repurposing approaches for COVID-19 management
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19). In this sense, the repositioning drugs for new indications can offer a better risk-versus-reward trade-off when compared to other drug development strategies, given that it makes use of drugs whose safety profile are already understood. Nonetheless, this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it
Computational Perspectives into Plasmepsins Structure—Function Relationship: Implications to Inhibitors Design
The development of efficient and selective antimalariais remains a challenge for the pharmaceutical industry. The aspartic proteases plasmepsins, whose inhibition leads to parasite death, are classified as targets for the design of potent drugs. Combinatorial synthesis is currently being used to generate inhibitor libraries for these enzymes, and together with computational methodologies have been demonstrated capable for the selection of lead compounds. The high structural flexibility of plasmepsins, revealed by their X-ray structures and molecular dynamics simulations, made even more complicated the prediction of putative binding modes, and therefore, the use of common computational tools, like docking and free-energy calculations. In this review, we revised the computational strategies utilized so far, for the structure-function relationship studies concerning the plasmepsin family, with special focus on the recent advances in the improvement of the linear interaction estimation (LIE) method, which is one of the most successful methodologies in the evaluation of plasmepsin-inhibitor binding affinity
A multilayer network approach for guiding drug repositioning in neglected diseases
Drug development for neglected diseases has been historically hampered due to lack of market incentives. The advent of public domain resources containing chemical information from high throughput screenings is changing the landscape of drug discovery for these diseases. In this work we took advantage of data from extensively studied organisms like human, mouse, E. coli and yeast, among others, to develop a novel integrative network model to prioritize and identify candidate drug targets in neglected pathogen proteomes, and bioactive drug-like molecules. We modeled genomic (proteins) and chemical (bioactive compounds) data as a multilayer weighted network graph that takes advantage of bioactivity data across 221 species, chemical similarities between 1.7 105 compounds and several functional relations among 1.67 105 proteins. These relations comprised orthology, sharing of protein domains, and shared participation in defined biochemical pathways. We showcase the application of this network graph to the problem of prioritization of new candidate targets, based on the information available in the graph for known compound-target associations. We validated this strategy by performing a cross validation procedure for known mouse and Trypanosoma cruzi targets and showed that our approach outperforms classic alignment-based approaches. Moreover, our model provides additional flexibility as two different network definitions could be considered, finding in both cases qualitatively different but sensible candidate targets. We also showcase the application of the network to suggest targets for orphan compounds that are active against Plasmodium falciparum in high-throughput screens. In this case our approach provided a reduced prioritization list of target proteins for the query molecules and showed the ability to propose new testable hypotheses for each compound. Moreover, we found that some predictions highlighted by our network model were supported by independent experimental validations as found post-facto in the literature.Fil: Berenstein, Ariel José. Fundación Instituto Leloir; Argentina. Universidad de Buenos Aires. Facultad de Ingeniería. Departamento de Física; ArgentinaFil: Magariños, María Paula. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús). Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús); ArgentinaFil: Chernomoretz, Ariel. Fundación Instituto Leloir; Argentina. Universidad de Buenos Aires. Facultad de Ingeniería. Departamento de Física; ArgentinaFil: Fernandez Aguero, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús). Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús); Argentin
- …